^
    20d
    Targeting eIF4G1-dependent translation in melanoma. (PubMed, bioRxiv)
    We previously identified SBI-756, a small molecule that interferes with the eIF4F assembly and overcomes melanoma resistance to BRAF inhibitors...Alone, M19-6 reduced melanoma growth and metastasis in a xenograft model. M19-6 offers a new therapeutic modality to overcome resistance and metastasis.
    Journal
    |
    EIF4G1 (Eukaryotic translation initiation factor 4 gamma, 1)
    |
    SBI-756
    1m
    The Bi-Steric Inhibitor RMC-5552 Reduces mTORC1 Signaling and Growth in Lymphangioleiomyomatosis. (PubMed, Am J Respir Cell Mol Biol)
    Rapamycin inhibition of LAF growth was rapidly reversed, but RMC-5552 inhibition was more durable. RMC-5552, through its potential to eradicate LAM cancer SLS cells, may have therapeutic benefit in LAM and other diseases with mTORC1 hyperactivity.
    Journal
    |
    TSC1 (TSC complex subunit 1) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)
    |
    MTOR mutation
    |
    RMC-5552
    1m
    Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, National Cancer Institute (NCI) | N=209 --> 17 | Trial completion date: Jun 2024 --> Nov 2025
    Enrollment change • Trial completion date
    |
    TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
    |
    TSC1 mutation • TSC2 mutation
    |
    sapanisertib (CB-228)
    2ms
    Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2024 --> Sep 2025
    Trial completion date • Combination therapy
    |
    AFP (Alpha-fetoprotein)
    |
    temozolomide • irinotecan • Fyarro (nanoparticle albumin-bound rapamycin)
    3ms
    DICE: Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) (clinicaltrials.gov)
    P2, N=134, Completed, Imperial College London | Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Nov 2023 | Trial primary completion date: Dec 2022 --> Nov 2023
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    paclitaxel • sapanisertib (CB-228)
    3ms
    Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors. (PubMed, Mol Oncol)
    In our study, we investigated how phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway inhibitors (TAK-228, everolimus and TAK-117) affect PD-L1 expression and function in preclinical bladder cancer cell models. These preclinical findings suggest that mTOR inhibition with TAK-228 can increase PD-L1 levels, potentially impacting the specific immune response against UC cells. This highlights the rationale for exploring the combination of mTOR inhibitors with ICIs in patients with advanced UC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • EGF (Epidermal growth factor) • IFNB1 (Interferon Beta 1)
    |
    PD-L1 expression • IFNG expression
    |
    everolimus • sapanisertib (CB-228) • serabelisib (MLN1117)
    4ms
    PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients. (PubMed, Heliyon)
    Further analysis found that PMEL expression negatively correlated with the reduction rate of TSC-RAMLs after mTORC1 inhibitor treatment (r = -0.50, p = 0.0022), both after 3 months (r = -0.47, p = 0.048) and 6 months of treatment (r = -0.52, p = 0.028). PMEL expression positively correlated with the tumor size of TSC-RAMLs, and inversely with the reduction rate of TSC-RAMLs after mTORC1 inhibitor treatment, which may suggest that PMEL may serve as a predictive biomarker for the efficacy of mTORC1 inhibitor treatment.
    Journal
    |
    PMEL (Premelanosome Protein) • PCSK1 (Proprotein Convertase Subtilisin/Kexin Type 1)
    4ms
    A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions (clinicaltrials.gov)
    P1, N=12, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    gemcitabine • Fyarro (nanoparticle albumin-bound rapamycin)
    4ms
    Characterization of Cancer Stem Cells in Laryngeal Squamous Cell Carcinoma by Single-cell RNA Sequencing. (PubMed, Genomics Proteomics Bioinformatics)
    Furthermore, bioinformatics analyses showed that drugs such as erlotinib, OSI-027, and ibrutinib selectively targeted the CSC-specifically expressed genes. In conclusion, our results represent the first comprehensive characterization of CSCs properties in LSCC at the single-cell level.
    Journal • Cancer stem
    |
    ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • PROM1 (Prominin 1) • SOX4 (SRY-Box Transcription Factor 4)
    |
    erlotinib • Imbruvica (ibrutinib) • AVTX-006
    5ms
    Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway. (PubMed, Mol Oncol)
    Using a combination of functional and metabolic assays, we evaluated a panel of PC cell lines with different PTEN/PIK3CA status for their sensitivity to multi-node PAM inhibitors (PI3K/mTOR: gedatolisib, samotolisib) and single-node PAM inhibitors (PI3Kα: alpelisib; AKT: capivasertib; mTOR: everolimus). Gedatolisib, as a single agent and in combination with other therapies, reported promising preliminary efficacy and safety in various solid tumor types. Gedatolisib is currently being evaluated in a Phase 1/2 clinical trial in combination with darolutamide in patients with mCRPC previously treated with an AR inhibitor, and in a Phase 3 clinical trial in combination with palbociclib and fulvestrant in patients with HR+/HER2- advanced breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor)
    |
    Ibrance (palbociclib) • everolimus • Piqray (alpelisib) • fulvestrant • Truqap (capivasertib) • gedatolisib (PF-05212384) • Nubeqa (darolutamide) • samotolisib (LY3023414)
    5ms
    X31025: Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=19, Completed, Avera McKennan Hospital & University Health Center | Active, not recruiting --> Completed | N=30 --> 19
    Trial completion • Enrollment change • Combination therapy • Metastases
    |
    PI3K (Phosphoinositide 3-kinases)
    |
    paclitaxel • sapanisertib (CB-228) • serabelisib (MLN1117)
    5ms
    Nitidine chloride inhibits mTORC1 signaling through ATF4-mediated Sestrin2 induction and targets IGF2R for lysosomal degradation. (PubMed, Life Sci)
    NC inhibits mTORC1 signaling through nutrient sensing and directly targets IGF2R for lysosomal degradation, providing mechanistic insights into the MOA of NC.
    Journal
    |
    ATF4 (Activating Transcription Factor 4) • TCF4 (Transcription Factor 4)
    5ms
    Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines. (PubMed, BMC Cancer)
    These results highlight the importance of ZFP36 activation in response to metformin treatment involving mTORC1 inhibition.
    Preclinical • Journal
    |
    AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • DCP2 (Decapping MRNA 2) • ZFP36 (ZFP36 Ring Finger Protein)
    |
    sirolimus • metformin
    5ms
    Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO) (clinicaltrials.gov)
    P2, N=37, Not yet recruiting, University of Oklahoma
    New P2 trial
    |
    fulvestrant • Fyarro (nanoparticle albumin-bound rapamycin)
    6ms
    Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study. (PubMed, Clin Genitourin Cancer)
    Although the primary endpoint was no met, sapanisertib and paclitaxel combination demonstrated clinical activity in a heavily pretreated population of mUC. This trial generates insight for future combination of sapaniserib with immunotherapy and/or antibody drug conjugates.
    P2 data • Journal • Combination therapy • IO biomarker • Metastases
    |
    NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    paclitaxel • sapanisertib (CB-228)
    6ms
    Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1; Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    Guardant360® CDx • MSK-IMPACT
    |
    sapanisertib (CB-228) • telaglenastat (CB-839)
    6ms
    BTCRC-BRE18-337: Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers (clinicaltrials.gov)
    P1/2, N=37, Active, not recruiting, Kari Wisinski | Trial completion date: Apr 2024 --> Jul 2024 | Trial primary completion date: Apr 2024 --> Jul 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    Talzenna (talazoparib) • gedatolisib (PF-05212384)
    7ms
    Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models. (PubMed, NPJ Breast Cancer)
    By using multiple functional assays, a panel of BC cell lines was evaluated for their sensitivity to four different PAM inhibitors: gedatolisib (pan-PI3K/mTOR inhibitor), alpelisib (PI3Kα inhibitor), capivasertib (AKT inhibitor), and everolimus (mTORC1 inhibitor). These results indicate that inhibition of multiple PAM pathway nodes by a pan-PI3K/mTOR inhibitor like gedatolisib may be more effective at inducing anti-tumor activity than single-node PAM inhibitors. A global Phase 3 study is currently evaluating gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- ABC.
    Preclinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    Ibrance (palbociclib) • everolimus • Piqray (alpelisib) • fulvestrant • Truqap (capivasertib) • gedatolisib (PF-05212384)
    7ms
    Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1; Trial completion date: Sep 2024 --> Jun 2025 | Trial primary completion date: Sep 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    Guardant360® CDx • MSK-IMPACT
    |
    sapanisertib (CB-228) • telaglenastat (CB-839)
    7ms
    Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=37, Completed, M.D. Anderson Cancer Center | Trial primary completion date: Jun 2022 --> Jul 2023
    Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    Tagrisso (osimertinib) • sapanisertib (CB-228) • alisertib (MLN8237)
    7ms
    Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Aadi Bioscience, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Pan tumor
    |
    TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
    |
    Fyarro (nanoparticle albumin-bound rapamycin)
    7ms
    Intronic miR-6741-3p targets the oncogene SRSF3: Implications for oral squamous cell carcinoma pathogenesis. (PubMed, PLoS One)
    We treated cells from an OSCC cell line SCC131 with 5-Azacytidine, a DNA methyltransferase inhibitor, to reactivate tumor suppressor miRNA genes silenced/downregulated due to DNA methylation. Our results revealed that miR-6741-3p plays a tumor-suppressive role in OSCC pathogenesis, in part, by directly regulating SRSF3. Based on our observations, we propose that miR-6741-3p may serve as a potential biological target in tumor diagnostics, prognostic evaluation, and treatment of OSCC and perhaps other malignancies.
    Journal
    |
    SRSF3 (Serine And Arginine Rich Splicing Factor 3)
    |
    azacitidine • MTI-31
    7ms
    mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (clinicaltrials.gov)
    P1/2, N=159, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Truqap (capivasertib) • vistusertib (AZD2014)
    7ms
    Prediction of Prognostic Features Based on Neutrophil-Related Genes for Lung Squamous Cell Carcinoma Reveals Immune Landscape and Drug Candidates. (PubMed, Rev Invest Clin)
    Moreover, prediction results from the CellMiner database revealed great correlations between drug sensitivity (e.g., Vinorelbine and PKI-587) and prognostic genes. (Rev Invest Clin. 2024;76(2):116-31).
    Journal • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    gedatolisib (PF-05212384) • vinorelbine tartrate
    8ms
    Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) (clinicaltrials.gov)
    P2, N=49, Active, not recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    sapanisertib (CB-228)
    8ms
    Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=39, Completed, Bradley A. McGregor, MD | Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Apr 2024
    Trial completion • Trial completion date • Metastases
    |
    sapanisertib (CB-228)
    8ms
    A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors. (PubMed, Cancers (Basel))
    Dual targeting of Aurora A kinase and mTOR resulted in marginal clinical benefit in a population of patients with refractory solid tumors, including pancreatic adenocarcinoma, though individual patients experienced significant response to therapy. Correlatives indicate apoptotic response and tumor immune cell infiltrate may affect clinical outcomes.
    P1 data • Journal • Metastases
    |
    ER (Estrogen receptor) • AURKA (Aurora kinase A)
    |
    ER positive
    |
    sapanisertib (CB-228) • alisertib (MLN8237)
    8ms
    Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    sapanisertib (CB-228)
    8ms
    Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=54, Recruiting, Celcuity Inc | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    gedatolisib (PF-05212384) • Nubeqa (darolutamide)
    9ms
    Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=40, Terminated, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Oct 2023 | Active, not recruiting --> Terminated; Other - Lapse in funding
    Trial completion date • Trial termination • Surgery
    |
    sapanisertib (CB-228)
    9ms
    Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. (PubMed, Lancet Oncol)
    Gedatolisib plus palbociclib and endocrine therapy showed a promising objective response rate compared with the published results for standard-of-care therapies and had an acceptable safety profile.
    P1 data • Journal • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HR positive • HER-2 negative • PIK3CA mutation • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • gedatolisib (PF-05212384)
    9ms
    RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=48, Recruiting, Nicholas Butowski | Active, not recruiting --> Recruiting
    Enrollment open
    |
    RMC-5552
    9ms
    Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    sapanisertib (CB-228)
    9ms
    A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial • Metastases
    |
    gemcitabine • Fyarro (nanoparticle albumin-bound rapamycin)
    10ms
    Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Surgery
    |
    sapanisertib (CB-228)
    10ms
    Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. (PubMed, Cancer Med)
    The combination of sapanisertib and ziv-aflibercept was generally tolerable and demonstrated anti-tumor activity in heavily pre-treated patients with advanced malignancies.
    P1 data • Journal • Combination therapy • Metastases
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV)
    10ms
    Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=83, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Jan 2024
    Trial completion • Trial completion date • Combination therapy • Surgery • Metastases
    |
    sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV)
    10ms
    Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=108, Active, not recruiting, Revolution Medicines, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    RMC-5552
    10ms
    mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (clinicaltrials.gov)
    P1/2, N=159, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Truqap (capivasertib) • vistusertib (AZD2014)
    10ms
    BTCRC-BRE18-337: Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers (clinicaltrials.gov)
    P1/2, N=37, Active, not recruiting, Kari Wisinski | Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    HER-2 negative • BRCA1 negative
    |
    Talzenna (talazoparib) • gedatolisib (PF-05212384)
    10ms
    Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors (clinicaltrials.gov)
    P1, N=96, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2024 --> Jan 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    PIK3CA mutation
    |
    Ibrance (palbociclib) • gedatolisib (PF-05212384)
    10ms
    Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=83, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Jan 2025
    Trial completion date • Combination therapy • Surgery • Metastases
    |
    sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV)